American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

ImageneBio, Inc.

$5.63 -0.35% NASDAQ: IMA · 15-min delayed

SAN DIEGO, California
Public · NASDAQ: IMA
17 employees

Visit website Follow

$63.7MMarket cap

$800.0KRevenue · FY2025

-$45.3MNet income

17Employees

IMANASDAQ

2025IPO

About ImageneBio, Inc.

ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment.

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.

Company facts

Type: Public · NASDAQ: IMA
Employees: 17
IPO date: Jul 28, 2025
Headquarters: 12526 HIGH BLUFF DRIVE
SAN DIEGO, California 92130
Phone: 857-343-8292
Industry: Pharmaceuticals
Website: Visit site

Registry IDs

Ticker: IMA Nasdaq
SEC CIK: 1835579
EIN: 811697316
SIC: 2836 BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Is this your company?

This profile is unclaimed — any authorized owner can claim it, control the page, and earn the Verified badge.

Claim this profile

Track American companies

Create a free account to follow ImageneBio, Inc. and get an email when it moves sharply — real market data, 15-minute delayed.

Create free account

Reported figures

Financial summary

Revenue FY2025: $800.0K
Net income: -$45.3M
Total assets: $153.0M
Market cap: $63.7M
Operating margin: -6056.4%
Net margin: -5668.6%

Source: SEC EDGAR · updated Jun 7, 2026

FY 2025

Financial statements

Income statement

Revenue: $800.0K
Operating expenses: $49.3M
Operating income: -$48.5M
Income tax: -$350.0K
Net income: -$45.3M
EPS (basic): $-9.64
EPS (diluted): $-9.64

Balance sheet

Total assets: $153.0M
Current assets: $140.3M
Total liabilities: $19.8M
Current liabilities: $11.2M
Shareholders’ equity: $133.1M

Cash flow

Operating cash flow: -$47.8M
Investing cash flow: -$5.8M
Financing cash flow: $135.5M
Net cash flow: $82.4M

Statements via Polygon.io (SEC filings)

NASDAQ: IMA

$5.63 -0.35%

15-minute delayed · data by Polygon.io

Past year

$4.55 $17.90

52-week range

Market cap: $63.7M
EPS (diluted): $-9.64
Shares outstanding: 11.3M
Open: —
Day range: –
Prev close: —
Volume: —
IPO date: Jul 28, 2025

Market data by Polygon.io · prices are 15-minute delayed

Auto-generated

At a glance

Reported a net loss of $45.3M in FY2025.
Trading 69% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review ImageneBio, Inc..

Write a review